ฐานข้อมูลอันตรกิริยาระหว่างสมุนไพรกับยาแผนปัจจุบัน

GINKGOACEAE Ginkgo biloba  L.
 Synonym

    none ...
 Thai / English name

  • แปะก๊วย*

[1-5] of 5 article(s) found

 หน้า  1  2  

[1] USE OF DIETARY SUPPLEMENTS AND THEIR INTERACTIONS WITH PRESCRIPTION DRUGS IN THE ELDERLY.
LY J,PERCY L,DHANANI S
AM J HEALTH SYST PHARM 2002 Vol.59(18),1759-62  $20273 [Full]

Part Used : ไม่ระบุ
Activity : DRUG INTERACTION
Solvent/Active Compound : -
Type of experiment : human
Type of animal : -
Type of study : Cross-section
N(Total) : 15
N(Treatment) : -
Sex : Both sex
Age : 78+-/6 yrs.
Route : Oral administration
Dose/Conc.(herb) : -
Duration : -
Type of interaction : P.Kinetics & P.Dynamics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : -
Result : Positive
Remark : Result: Ginkgo biloba + Aspirin or another NSAID = Increased risk of bleeding (No. Potential or Possible Interactions = 5 of 45)
Note : Subject total: Subjects were veterans over the age of 65 years who are frail and have complex medical and psychosocial problems.
[2] POTENTIAL INTERACTIONS BETWEEN PHARMACEUTICALS AND NATURAL HEALTH PRODUCTS IN CANADA.
SINGH SR,LEVINE MAH
J CLIN PHARMACOL 2007 Vol.47(2),249-58  $20337 [Full]

Part Used : ไม่ระบุ
Activity : DRUG INTERACTION
Solvent/Active Compound : -
Type of experiment : human
Type of animal : -
Type of study : Cross-section
N(Total) : 11,424
N(Treatment) : -
Sex : Both sex
Age : >/=18 years
Route : Oral administration
Dose/Conc.(herb) : -
Duration : 2000-2001
Type of interaction : Pharmacokinetics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : -
Result : Positive
Remark : Ginkgo biloba was associated with the potential for major bleeding due to combined use with acetylsalicylic acid (ASA) or warfarin.
Note : Subjects: Of the adult National population Health Survey respondents (n=11,424), 9.3% reported the use of at least 1 natural health product in the past 2 days in 2000-2001.
[3] DOES GINKGO BILOBA SPECIAL EXTRACT EGB 761 PROVIDE ADDITIONAL EFFECTS ON COAGULATION AND BLEEDING WHEN ADDED TO ACETYLSALICYLIC ACID 500 MG DAILY?.
WOLF HRD
DRUGS R D 2006 Vol.7(3),163-72  $21301 [Full]

Part Used : ใบ
Activity : PLATELET AGGREGATION INHIBITION
Solvent/Active Compound : EGb761
Type of experiment : human
Type of animal : -
Type of study : Cross over
N(Total) : 50 (M/F=50/-)
N(Treatment) : 50 (M/F=50/-)
Sex : Male
Age : 20-44 yrs. (mean 27.2+/-4.9)
Route : Oral administration
Dose/Conc.(herb) : EGb 761 120 mg of dry extract twice daily
Duration : 7 days
Type of interaction : Pharmacokinetics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : 500 mg daily
Result : Positive
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.
Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบ
Activity : DRUG INTERACTION
Solvent/Active Compound : EGb761
Type of experiment : human
Type of animal : -
Type of study : Double-blind trial
N(Total) : 50 (M/F=50/-)
N(Treatment) : 50 (M/F=50/-)
Sex : Male
Age : 20-44 yrs. (mean 27.2+/-4.9)
Route : Oral administration
Dose/Conc.(herb) : EGb 761 120 mg of dry extract twice daily
Duration : 7 days
Type of interaction : Pharmacokinetics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : 500 mg daily
Result : Positive
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.
Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบ
Activity : DRUG INTERACTION
Solvent/Active Compound : EGb761
Type of experiment : human
Type of animal : -
Type of study : Cross over
N(Total) : 50 (M/F=50/-)
N(Treatment) : 50 (M/F=50/-)
Sex : Male
Age : 20-44 yrs. (mean 27.2+/-4.9)
Route : Oral administration
Dose/Conc.(herb) : EGb 761 120 mg of dry extract twice daily
Duration : 7 days
Type of interaction : Pharmacokinetics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : 500 mg daily
Result : Positive
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.
Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
Part Used : ใบ
Activity : PLATELET AGGREGATION INHIBITION
Solvent/Active Compound : EGb761
Type of experiment : human
Type of animal : -
Type of study : Double-blind trial
N(Total) : 50 (M/F=50/-)
N(Treatment) : 50 (M/F=50/-)
Sex : Male
Age : 20-44 yrs. (mean 27.2+/-4.9)
Route : Oral administration
Dose/Conc.(herb) : EGb 761 120 mg of dry extract twice daily
Duration : 7 days
Type of interaction : Pharmacokinetics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : 500 mg daily
Result : Positive
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA + EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of measns: 1.01, 90% Cl 0.86, 1.19) and agonist-induced platelet aggregation (collagen-induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00 , 90% Cl 0.95, 1.05; adenosine diphosphate-induced platelet aggregation - ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06). Both treatments were well tolerated , and both the number and nature of adverse events in the two groups were similar.
Note : 50 healthy male subjects were randomly allocated in equal numbers to one of two possible treatment sequences, i.e. ASA followed by ASA + EGb 761 or ASA + EGb 761 followed by ASA. Each treatment lasted 7 days; the washout period between treatments was 3 weeks. Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo-coated tablet in the morning and placebo tablet + placebo-coated tablet in the evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg-coated tablet in the morning and placebo tablet + EGb 761 120 mg-coated tablet in the evening) resulting in a daily dose of ASA 500 mg in the ASA group and 500 mg ASA + 240 mg EGb 761 in the ASA + EGb 761 group.
[4] DOES GINKGO BILOBA SPECIAL EXTRACT EGB 761 PROVIDE ADDITIONAL EFFECTS ON COAGULATION AND BLEEDING WHEN ADDED TO ACETYLSALICYLIC ACID 500MG DAILY?
WOLF HRD
DRUGS R D 2006 Vol.7(3),163-72  335869 [Abstract]

Part Used : ใบ
Activity : DRUG INTERACTION
Solvent/Active Compound : Ginkgo biloba special extraction (EGb 761)
Type of experiment : human
Type of animal : -
Type of study : Double-blind trial
N(Total) : 50
N(Treatment) : 50
Sex : Male
Age : 20-44 years
Route : Oral administration
Dose/Conc.(herb) : *
Duration : **
Type of interaction : Pharmacodynamics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : -
Result : Equivocal
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA +EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of means 1.01, 90% Cl 0.86, 1.19) and agonist - induced platelet aggregation (collagen - induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% Cl 0.95, 1.05; ADP-induced platelet aggregation -ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06).
Note : *Dose: Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo - coated tablate in the morning and placebo tablet + placebo - coated tablet in evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg - coated tablet in the morning and placebo tablet + EGb 761 120 mg - coated tablet in evening. **Duration: Each treatment lasted 7 days, the washout period between treatment was 3 weeks. - Data incomplete.
Part Used : ใบ
Activity : ANTICOAGULANT ACTIVITY
Solvent/Active Compound : Ginkgo biloba special extraction (EGb 761)
Type of experiment : human
Type of animal : -
Type of study : Double-blind trial
N(Total) : 50
N(Treatment) : 50
Sex : Male
Age : 20-44 years
Route : Oral administration
Dose/Conc.(herb) : *
Duration : **
Type of interaction : Pharmacodynamics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : -
Result : Equivocal
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA +EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of means 1.01, 90% Cl 0.86, 1.19) and agonist - induced platelet aggregation (collagen - induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% Cl 0.95, 1.05; ADP-induced platelet aggregation -ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06).
Note : *Dose: Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo - coated tablate in the morning and placebo tablet + placebo - coated tablet in evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg - coated tablet in the morning and placebo tablet + EGb 761 120 mg - coated tablet in evening. **Duration: Each treatment lasted 7 days, the washout period between treatment was 3 weeks. - Data incomplete.
Part Used : ใบ
Activity : PLATELET AGGREGATION INHIBITION
Solvent/Active Compound : Ginkgo biloba special extraction (EGb 761)
Type of experiment : human
Type of animal : -
Type of study : Double-blind trial
N(Total) : 50
N(Treatment) : 50
Sex : Male
Age : 20-44 years
Route : Oral administration
Dose/Conc.(herb) : *
Duration : **
Type of interaction : Pharmacodynamics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : -
Result : Equivocal
Remark : Results: Acetylsalicylic acid (ASA) and the combination of ASA +EGb 761 exerted quite similar effects on all coagulation parameters measured, including bleeding time (ASA alone: 4.1 min before therapy, 6.2 min after therapy; ASA + EGb 761: 4.2 min before therapy, 6.3 min after therapy; ratio of means 1.01, 90% Cl 0.86, 1.19) and agonist - induced platelet aggregation (collagen - induced platelet aggregation - ASA: 84.5% before therapy, 81.0% after therapy; ASA + EGb 761: 86.6% before therapy, 81.0% after therapy; ratio of means: 1.00, 90% Cl 0.95, 1.05; ADP-induced platelet aggregation -ASA: 72.6% before therapy, 47.2% after therapy; ASA + EGb 761: 71.7% before therapy, 44.8% after therapy; ratio of means: 0.95, 90% Cl 0.85, 1.06).
Note : *Dose: Study medication was taken twice daily (ASA group: ASA 500 mg tablet + placebo - coated tablate in the morning and placebo tablet + placebo - coated tablet in evening; ASA + EGb 761 group: ASA 500 mg tablet + EGb 761 120 mg - coated tablet in the morning and placebo tablet + EGb 761 120 mg - coated tablet in evening. **Duration: Each treatment lasted 7 days, the washout period between treatment was 3 weeks. - Data incomplete.
[5] SPONTANEOUS HYPHEMA ASSOCIATED WITH INGESTION OF GINKGO BILOBA EXTRACT.
ROSENBLATT M, MINDEL J
N ENGL J MED 1997 Vol.(),  414709 [Abstract]

Part Used : ไม่ระบุ
Activity : HEMORRHAGIC EFFECT
Solvent/Active Compound : Ginkoba tablet
Type of experiment : human
Type of animal : -
Type of study : Case report
N(Total) : 1
N(Treatment) : 1
Sex : Male
Age : 70 years
Route : Oral administration
Dose/Conc.(herb) : Ginkoba tablet twice daily, each tablet contained 40 mg of concentrated (50:1) extract of G. biloba tree.
Duration : 1 weeks
Type of interaction : P.Kinetics & P.Dynamics
Interaction with drug : Aspirin*/Acetylsalicylic acid/ASA/Ecosprin
Dose/Conc.(drug) : 325 mg tablet/day
Result : -
Remark : A 70-year-old man presented after two days of recurrent blurred vision in the right eye, with each episode lasting 15 minutes, during which he could perceive a red discoloration through his cornea. The patient stopped taking the ginkgo extract but continued to take daily aspirin, and there was no recurrence of bleeding over a three month follow-up period.
Note : Data incomplete

 หน้า  1  2  


Web Link ที่เกี่ยวข้อง

ที่อยู่

สำนักงานข้อมูลสมุนไพร
คณะเภสัชศาสตร์ มหาวิทยาลัยมหิดล
447 ถนนศรีอยุธยา เขตราชเทวี กรุงเทพฯ 10400
โทรศัพท์ 0-2354-4327,
0-2644-8677-91 ต่อ 5305, 5316
โทรสาร 0-2354-4327
email:  headpypi@mahidol.ac.th